Musely is a technology company.
Musely has raised $22.0M across 2 funding rounds.
Musely has raised $22.0M in total across 2 funding rounds.
Musely has raised $22.0M in total across 2 funding rounds.
Musely's investors include DCM, 8-Bit Capital, A Capital, Alsop Louie Partners, AME Cloud Ventures, Base Partners, Binary Capital, Matt Ocko, Zachary Bogue, Draper Associates, DST Global, Emergence Capital.
Musely is a telemedicine company specializing in personalized prescription treatments for skin, hair, hormonal health, and longevity, connecting patients with board-certified dermatologists and pharmacists via an online platform.[1][2][3][5] It serves primarily women aged 30-90 facing complex conditions like hyperpigmentation, aging, melasma, hair loss, and menopause, solving accessibility barriers in traditional dermatology through custom-compounded medications delivered to homes.[1][2][4][5] Launched with two skincare products in 2019, Musely has grown rapidly, serving over 1 million patients, dispensing 5 million prescriptions, raising $22.19M in Series B-II funding, and expanding to 24 treatments—including the 2025 Age Well Pill for longevity—while achieving profitable growth and high retention as the fastest-growing telemedicine brand.[3][5]
Musely was founded in 2019 by serial entrepreneur Jack Jia, a Silicon Valley veteran whose prior ventures focused on technology rather than healthcare.[2][3][5] The idea emerged accidentally from an earlier content app for women sharing lifestyle tips, which exploded to a million shares with skincare as the top category; Jia pivoted by inviting top brands but identified a gap in personalized, effective treatments after his wife struggled with generic products for stubborn issues like melasma.[1][2] Early traction came from launching two products—spot cream for hyperpigmentation and anti-aging cream—targeting women 30-60, which quickly expanded the demographic to 90-year-olds and built a foundation in teledermatology.[2] Pivotal moments include scaling to over 1 million patients in six years and recent expansions into hair, women's health, and longevity, fueled by customer feedback and a human-AI customer experience model.[2][5]
Musely rides the telemedicine and digital health wave, accelerated by post-pandemic demand for remote, personalized care in underserved areas like dermatology and longevity medicine.[1][3][5] Timing aligns with aging populations seeking "healthspan" solutions—extending vital years—amid market forces like e-commerce health (11K+ companies) and telehealth growth (3K+ firms), where Musely stands out via compounding tech and physician-pharmacist integration.[3][5] It influences the ecosystem by disrupting traditional dermatology's inaccessibility, proving scalable models for preventive care (e.g., from skincare to pills), and setting benchmarks in retention and profitability that smaller telehealth players emulate.[2][5]
Musely's trajectory points to deeper longevity and hormonal health expansions, leveraging its 1M+ patient data for AI-enhanced personalization and new treatments beyond the Age Well Pill.[5] Trends like preventive telehealth, compounded meds deregulation, and aging demographics will propel growth, potentially positioning it as a multi-billion player if it sustains profitability amid competition. Its evolution from skincare startup to telemedicine leader underscores accessible science's power—redefining how we age well, one prescription at a time.
Musely has raised $22.0M across 2 funding rounds. Most recently, it raised $16.0M Series B in September 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2014 | $16.0M Series B | DCM | |
| Nov 1, 2013 | $6.0M Series A | 8-Bit Capital, A Capital, Alsop Louie Partners, AME Cloud Ventures, Base Partners, Binary Capital, DCM, Matt Ocko, Zachary Bogue, Draper Associates, DST Global, Emergence Capital, Ensemble VC, Goat Capital, Hardware Club, Maven Ventures, Scheinman Angel Fund, Sequoia Capital, Seven Seven Six, Sherpalo Ventures, Sound Ventures, TSVC Capital, Wisdom LLP, Y Combinator, Bart Swanson, Bill Tai, Emmett Shear, Erik Moore, Kyle Vogt, Michael Levit, Michael Rapino, Ronny Conway, Shane Battier, Shervin Pishevar |